Pd-l1 expression confers better prognosis in locally advanced oral squamous cell carcinoma

54Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Clinical trials with therapies targeting immune checkpoint molecules have shown promising results in several tumor types. However, the predictive and prognostic values of these immunological factors for locally advanced oral squamous cell carcinomas (LAOSCC) remain unclear. Our purpose was to evaluate the expression and prognostic value of programmed cell deathligand1 (PD-L1) and PD-L2 and to correlate their expression with the degree of infiltration by CD8+ cells in LAOSCC. Patients and Methods: A total of 84 patients with LAOSCC were included. PD-L1, PD-L2 and CD8 expression was detected in the tumor tissue using immunohistochemistry and was tested for correlation with clinical outcome. Results: PDL1 and PD-L2 were expressed in 52.4% and 23.8% of LAOSCC cases, respectively. PD-L1 positivity was significantly associated with superior disease-free (p=0.024) and overall (p=0.008) survival of the patients and retained significance in multivariate analysis. PD-L1 positivity was correlated with CD8 density. Conclusion: PD-L1 expression was associated with CD8+ tumor-infiltrating lymphocytes and better outcome in patients with LAOSCC.

Cite

CITATION STYLE

APA

Kogashiwa, Y., Yasuda, M., Sakurai, H., Nakahira, M., Sano, Y., Gonda, K., … Sugasawa, M. (2017). Pd-l1 expression confers better prognosis in locally advanced oral squamous cell carcinoma. Anticancer Research, 37(3), 1417–1424. https://doi.org/10.21873/anticanres.11465

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free